Hutchmed (China) (0013) said China’s National Medical Products Administration has granted conditional approval for a new drug application for ORPATHYS (savolitinib), according to Ming Pao.
The company said the approval is for treating adult patients with locally advanced or metastatic gastric cancer or gastroesophageal junction (GC/GEJ) adenocarcinoma with MET gene amplification who have failed at least two systemic therapies.
STOCKS | Hutchmed (China) Says ORPATHYS Approved in China for MET-Amplified GC/GEJ Cancer
2026-07-02 10:33:31
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
STOCKS | Digital China Wins China Mobile PC Server Procurement Contract for 2026–2027Next article：
和黄医药：沃瑞沙ORPATHYS获中国大陆附条件批准
